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Summary
By studying a large series of 157 patients, we found that
complex I (33%), complex IV (28%), and complex IIV
(28%) deficiencies were the most common causes of res-
piratory chain (RC) defects in childhood. Truncal hy-
potonia (36%), antenatal (20%) and postnatal (31%)
growth retardation, cardiomyopathy (24%), encepha-
lopathy (20%), and liver failure (20%) were the main
clinical features in our series. No correlation between
the type of RC defect and the clinical presentation was
noted, but complex I and complex IIV deficiencies
were significantly more frequent in cases of cardiomy-
opathy ( ) and hepatic failure ( ), respec-P ! .01 P ! .05
tively. The sex ratio (male/female) in our entire series
was mostly balanced but was skewed toward males be-
ing affected with complex I deficiency (sex ratio R 
). Interestingly, a high rate of parental consanguinity1.68
was observed in complex IV (20%) and complex IIV
(28%) deficiencies. When parental consanguinity was
related to geographic origin, an even higher rate of in-
breeding was observed in North African families (76%,
). This study gives strong support to the viewP ! .01
that an autosomal recessive mode of inheritance is in-
volved in most cases of mitochondrial disorders in child-
hood, a feature that is particularly relevant to genetic
counseling for this devastating condition.
Introduction
Owing to the twin genetic origins of the mitochondrial
respiratory chain (RC), any mode of inheritance can be
observed for hereditary defects of oxidative phosphor-
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ylation—that is, sporadic, autosomal recessive, autoso-
mal dominant, X-linked, or maternal inheritance. In-
deed, among the hundreds of genes encoding the RC
components, most are located in the nucleus and un-
dergo classic Mendelian inheritance, whereas a few genes
are mitochondrially encoded (13 RC subunits) and
therefore follow a maternal inheritance. This genetic het-
erogeneity hinders gene identification and makes coun-
seling for RC deficiency particularly hazardous, espe-
cially since (1) mtDNA mutations/deletions are identified
in !7% of cases (Wong and Liang 1997) and (2) nuclear
gene mutations are seldom recognized. Indeed, apart
from succinate dehydrogenase deficiency (Bourgeron et
al. 1995) and Barth syndrome (Bione et al. 1996), sys-
tematic sequence analysis hitherto has failed to detect
any deleterious base changes in the nuclear genes with
influence on the mitochondrial RC.
In an attempt to determine the respective roles of
mtDNA and nuclear DNA mutations in the genetic de-
fects of oxidative phosphorylation, we have studied the
sex ratio, the rate of parental consanguinity, and the
parental age at time of birth of the proband, for a large
series of 157 respiratory-enzyme–deficient patients. The
observation of a high rate of parental consanguinity in
cytochrome oxidase (COX) deficiency (either isolated or
associated with complex I deficiency) gives strong sup-
port to the view that hitherto unknown nuclear genes
account for most cases of COX deficiency, an observa-
tion that is highly relevant to both gene cloning and
genetic counseling for this devastating condition.
Material and Methods
A total of 157 patients, from 148 families, were in-
cluded in this study. Inclusion criteria were (1) a defect
of oxidative phosphorylation, regardless of the present-
ing symptom or age at onset, that has been fully doc-
umented on at least one tissue sample from the proband
(muscle, liver, or endomyocardial biopsy; circulating
lymphocytes or cultured skin fibroblasts) and (2) the
availability of detailed clinical and laboratory infor-
mation on the disease.
von Kleist-Retzow et al.: Consanguinity in COX Deficiency 429
Figure 1 A, Distribution of respiratory-enzyme deficiencies. B,
Geographic origin of affected individuals. Italicized numbers indicate
number of consanguineous families/total number of families.
In each case, a genetic consultation allowed (1) the
identification of the two or three major symptoms; (2)
the recognition of minor symptoms in parents and sib-
lings; (3) the drawing of an extensive pedigree, with
particular attention to known consanguinity, sponta-
neous abortions, unexplained deaths, and similar cases
in the sibship or in previous generations; and (4) the
detection of erroneous diagnoses, improper tissue han-
dling, and possible phenocopies. Relatives were consid-
ered to be affected with the same disease if they presented
a similar enzyme deficiency and/or experienced the same
clinical symptoms.
The mitochondrial RC, which catalyzes the oxidation
of fuel molecules by oxygen and the concomitant energy
transduction into ATP, is divided into five functional
units or complexes: complex I (NADH–coenzyme Q
[CoQ] reductase; at least 43 subunits, 7 of which are
encoded by mtDNA), complex II (succinate-CoQ re-
ductase; 4 nuclear-encoded subunits), complex III
(CoQH2–cytochrome c reductase; 11 subunits, 1 of
which is encoded by mtDNA), complex IV (COX; 13
subunits, 3 of which are encoded by mtDNA), and com-
plex V (ATPase; 14 subunits, 2 of which are encoded
by mtDNA). All complex activities were measured as
described elsewhere (Rustin et al. 1994). On the basis
of the enzyme deficiency detected, our 157 patients were
split into five groups: isolated complex I, II, III, or IV
deficiency and combined complex IIV deficiency. In
each subgroup, we determined the mean sex ratio (male/
female), the mean parental age at time of birth of the
proband, the rate of spontaneous abortion, and the rate
of parental consanguinity. Results were compared to a
control population by use of the Student’s t-test or the
x2 test.
Results
Complex I (33%), complex IV (28%), and complex
IIV (28%) deficiencies showed similar frequencies in
our series, whereas complex II (4%) and complex III
(7%) deficiencies were far less frequent (fig. 1A). All
patients were evaluated for alterations within the
mtDNA: we found two deletions and two MELAS (mi-
tochondrial myopathy, encephalopathy, lactic acidosis,
and strokelike episodes) A3243G point mutations in pa-
tients with complex IIV deficiency and two MELAS
A3243G point mutations and one MERRF (myoclonic
epilepsy with ragged red fibers) A8344G point mutation
in patients with complex I deficiency (overall rate 4.5%).
Most patients were of western European (43%) or
North African (11%) ancestry, but ethnic origin re-
mained questionable or uncertain in 25% of patients
(fig. 1B). We first looked at the clinical presentation of
the disease in our series. Truncal hypotonia, antenatal
and postnatal growth retardation, cardiomyopathy, en-
cephalopathy (with or without seizures) and liver failure
were the main clinical features (table 1). Interestingly,
when the patients were split into five groups based on
the type of RC deficiency, complex I deficiency appeared
to be significantly more frequent in patients with car-
diomyopathy ( ). Similarly, complex IIV defi-P ! .01
ciency was significantly more frequent in patients with
hepatic failure ( ), and complex IV deficiency wasP ! .05
significantly more frequent in patients with gut involve-
ment ( ). In addition, complex IIV deficiencyP ! .05
was less frequent in spastic patients ( ). No sig-P ! .05
nificant differences between subtypes were found for the
other clinical symptoms (table 1).
A remarkably high rate of parental consanguinity was
observed in families of North African ancestry (76%;
fig. 1B), with the mean rates of parental consanguinity
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Figure 2 Rate of parental consanguinity in respiratory-enzyme
deficiency. The proportion (%) of proven consanguinity is given.
Table 1
Frequency of Clinical Symptoms and Findings, for Our Entire Series and for Each Type of Respiratory-Enzyme Deficiency
SYMPTOM
FREQUENCY
(%) NO. OF PATIENTS
All Complexes
[ ; ]n  157 N  148
Complex I
[ ; ]n  52 N  51
Complex IV
[ ; ]n  44 N  41
Complex IIV
[ ; ]n  44 N  40
Complex II
[ ; ]n  6 N  6
Complex III
[ ; ]n  11 N  10
Truncal hypotonia 36 35 39 36 4 2
Growth failure 31 25 36 34 2 3
Cardiomyopathy 24 35∗ 9∗ 32∗ 1 1
IUGR 20 25 23 11 0 3
Encephalopathy 20 23 23 18 1 0
Liver failure 20 12∗∗ 20∗∗ 34∗∗ 0 1
Cranial nerve
involvement 18 19 18 16 1 2
Myopathy 13 12 14 14 2 0
Spasticity 11 13∗∗ 18∗∗ 0∗∗ 1 2
Basal-ganglia
involvement 8 10 7 9 1 0
Ocular involvement 8 8 11 7 0 1
Gut involvement 8 4∗∗ 18∗∗ 7∗∗ 0 0
Cerebellar syndrome 8 8 9 5 1 1
Mental retardation 8 6 5 11 1 1
Renal involvement 8 0 9 9 1 3
Facial dysmorphism 8 6 9 9 1 0
Pancytopenia 7 6 9 9 0 0
Malformation 3 4 2 5 0 0
Peripheral
neuropathy 3 0 7 2 0 0
Ketoacidotic coma 3 4 0 2 0 1
Endocrine
involvement 2 4 0 0 0 1
Fetal distress 2 2 0 2 0 1
Hypermethioninemia 1 0 2 2 0 0
NOTE.—Owing to the small size of the sample, data for clinical symptoms for complex II and complex III deficiencies are given in absolute
values. n  total no. of patients; and N  total no. of families.
∗ .P ! .01
∗∗ .P ! .05
in the corresponding North African countries within the
range 29%–49% ( ) (Khlat 1997). A similar trendP ! .01
was noted in families of western European origin, 3%
of which were consanguineous, as compared with a
mean parental consanguinity of !1% in a corresponding
control population (Vogel and Motulsky 1997, p. 554).
Notably, high rates of parental consanguinity were ob-
served in families of children with complex IV (20%)
or complex IIV (28%) deficiency in our series. The
rate was lower among families of patients with complex
I (10%), complex II (17%), or complex III (10%) de-
ficiency (fig. 2).
Several pedigrees provided clinical and/or enzymolog-
ical evidence of recurrence of the disease in the offspring
of consanguineous parents (fig. 3). The observation of
several pedigrees that show more than one affected in-
dividual with apparently unrelated parents and that are
not suggestive of maternal transmission gives additional
support to the view that autosomal recessive genes are
involved (fig. 3).
The mean parental age at birth of the affected child
Figure 3 Pedigrees of consanguineous and multiplex families. Arrows indicate index patients. For pedigrees with consanguineous parents,
more than two generations are included only if there are contributing events in other generations. Pedigrees 1–18, Complex I deficiency. 1, a:
died age 2 years, encephalopathy, truncal hypotonia, neonatal distress. 2, a and b: died age 3 mo, liver failure; c: died age 4.5 mo, liver cirrhosis,
nephrocalcinosis; and d: died age 3 mo, liver failure, nephrocalcinosis. 3, a: truncal hypotonia, nystagmus, dysmorphism, delayed motor
milestones. 4, a: died age 5 mo, Leigh syndrome. 5, a: died age 3 d, cardiomyopathy, acidosis; b: died age 2 d, cardiomyopathy, acidosis; and
c: died age 2 wk, cardiomyopathy. 6, a: died age 7 mo, cardiomyopathy; and b: died age 8 mo, truncal hypotonia, cardiomyopathy. 7, a: died
age 1 year; and b: truncal hypotonia, encephalopathy, liver involvement. 8, a: died age 1 year, growth failure, truncal hypotonia, liver failure,
encephalopathy, ketoacidotic coma; and b: growth failure, hepatomegaly. 9, a: died age 10 mo, Leigh syndrome; and b: died age 7 mo, neurologic
involvement. 10, a: died age 2 mo; and b: died age 3 mo, intrauterine growth retardation (IUGR), neutropenia, cardiomyopathy, Barth syndrome.
11, a: died age 6 d, cardiomyopathy; and b: truncal hypotonia, cardiomyopathy. 12, a: died age 45 d, IUGR, diarrhea; and b: IUGR, gut
involvement, growth failure, diabetes, facial dysmorphism, liver involvement. 13, a and b: died age 3 mo; c: died age 10 mo, cardiomyopathy,
encephalopathy, truncal hypotonia, growth failure; and d: cardiomyopathy. 14, a: died age 2 d, IUGR, hydrocephaly; b: died age 1 d, premature,
infantile respiratory distress syndrome; c: died age 1 d, cardiomyopathy; and d: died age 3 mo, IUGR, cardiomyopathy, pancytopenia, facial
dysmorphism. 15, a, b, c, and d: Barth syndrome. a: died age 2.5 mo; b: died age 4 mo; and c: died age 2 years. 16, a and b: Alpers syndrome.
b: died age 2 years. 17, a: died age 6 mo, lactic acidosis; b: died age 5 mo, convulsions, truncal hypotonia, ketoacidotic coma; and c: died age
5 mo, growth failure, truncal hypotonia, multiorgan failure. 18, a: died age 7 mo, encephalopathy, lactic acidosis; b: mental retardation; and
c: truncal hypotonia, mental retardation, spasticity, leukodystrophy, optic atrophy, nystagmus. Pedigree 19, Complex II deficiency. a and b:
truncal hypotonia, mental retardation; and c and d: discontinued pregnancies (i.e., affected fetuses). Pedigrees 20 and 21, Complex III deficiency.
20, a: growth failure, renal involvement, mild mental retardation. 21, a: IUGR, neonatal distress, mental retardation; and b: died age 6 d,
IUGR, ketoacidotic coma, truncal hypotonia. Pedigrees 22–36, Complex IV deficiency. 22, a: died age 6 mo. 23, a: stillborn; b: died age 3 mo,
vomiting; c: died age 2 mo, truncal hypotonia, retinal dystrophy, renal involvement, spasticity; d: age at death unknown, truncal hypotonia,
renal involvement.
Figure 3 (continued) 24, a and b: leukodystrophy, renal involvement, growth failure; a: age at death unknown, truncal hypotonia,
retinal dystrophy; and b: died age 3 years, spasticity. 25, a: encephalopathy, convulsions. 26, a: IUGR, gut involvement, growth failure. 27, a
and b: died during neonatal period; and b: truncal hypotonia, convulsions. 28, a: cerebellar syndrome, growth failure, peripheral neuropathy,
retinal dystrophy, strabismus; and b: strabismus, muscular wasting. 29, a: died age 9 mo, encephalopathy, leukodystrophy; and b: leukodystrophy,
peripheral neuropathy. 30, a: died age 27 mo, IUGR, liver failure; and b: sensorineural deafness, cataract, liver involvement, gut involvement,
growth failure, facial dysmorphism, mental retardation. 31, a: died age 2 years; and b: encephalopathy, deafness, blindness. 32, a: died age 4
mo, hypoglycemia, liver failure; and b: liver failure, truncal hypotonia. 33, a: died age 3 mo, IUGR, sudden infant death syndrome; b: IUGR,
dysmorphism, mental retardation, spasticity; and c: IUGR, dysmorphism, mental retardation, spasticity, growth retardation. 34, a: died age 6
mo, truncal hypotonia, muscular wasting; b: died at birth; c: died by accident; d: truncal hypotonia, cystinuria, muscular wasting; and e: truncal
hypotonia, vomiting episodes, cystinuria, growth failure. 35, a: died age 4 wk, IUGR, cardiomyopathy; b: died age 3 mo, IUGR, cardiomyopathy,
truncal hypotonia. 36, a: died age 1 mo, limb paralysis; b: died age 11 mo, vomiting; c: died age 4 years, by accident; d: died age 2 mo,
convulsions, truncal hypotonia; and e: died age 5 d, truncal hypotonia, neonatal distress. Pedigrees 37–51, Complex IIV deficiency. 37, a, b,
and c: cause of death unknown; d: died age 3 years, convulsions, blindness; and e: microcephaly, anemia, developmental delay. 38, a: died age
14 years, leukemia; b: died age 4 mo, encephalitis; c: died age 43 years, cardiomyopathy, convulsions, optic neuropathy; and d: cardiomyopathy,
cerebellar syndrome, scoliosis. 39, a: died age 2 mo; b: died age 7 d; and c: died age 10 d, IUGR, cerebellar hypoplasia, hypoplasia of corpus
callosum, cortical atrophy, hypoventilation. 40, a: died age 5 d, truncal hypotonia, respiratory failure. 41, a: died age 2 years, IUGR, convulsions,
facial dysmorphism; and b: fetuses affected. 42, a: died age 3 d, hepatomegaly, neurologic distress; and b: liver involvement, growth failure,
gut involvement. 43, a, b, and c: liver and ocular involvement; and d: prenatal diagnosis. 44, a and b: died during neonatal period; and c: died
age 3 mo, truncal hypotonia, liver failure, renal involvement. 45, a: died age 21 mo, growth failure, encephalopathy, liver failure. 46, a: died
age 4 years, Leigh syndrome, hypoglycemia, liver failure; and b: died age 3.5 years, encephalopathy, hypoglycemia, liver failure, truncal hypotonia.
47, a: encephalopathy, growth failure, liver failure, facial dysmorphism. 48, a: facial paralysis, migraine, walking problems; b: died age 5 mo,
Leigh syndrome; c: age at death unknown, Leigh syndrome; and d: died age 7 mo, truncal hypotonia. 49, a: cardiomyopathy, deafness, growth
failure. 50, a: died age 5 mo, cardiomyopathy; and b: dizygote, died age 6 mo, cardiomyopathy. 51, a and b: cardiomyopathy.
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Table 2
Sex Ratios for Respiratory-Enzyme Deficiencies
DEFICIENCY
RATIO FOR ALL
FAMILIES
RATIO FOR NONCON-
SANGUINEOUS
FAMILIES
Patients
Only
 Affected
Sibship
Patients
Only
 Affected
Sibship
Complex I 1.36 1.68 1.12 1.45
Complex IV .57 .77 .47 .75
Complex IIV 1.15 1.00 1.33 1.27
Figure 4 Parental age, in respiratory-enzyme deficiency. The mean value is shown by a horizontal line; the range of absolute values is
indicated by a vertical line; and the box represents the 25th–75th percentile of obtained data. For each group, the number of patients (n) from
which data were available is shown above each box.
was similar among the biochemical subtypes and did not
significantly differ from the mean parental age in western
Europe (fig. 4) (Bouvet et al. 1974). Similar results were
observed when parental age in the subgroup of sporadic
cases was compared (data not given). Yet, a nonsignif-
icant increase of mean paternal age was noted in the
subgroup of complex III–deficient children (fig. 4).
Finally, we determined the sex ratios in our entire
series and in each biochemical subtype. The sex ratio
was mostly balanced among patients with complex IIV
deficiency (sex ratio and 1.27, for all families andR  1
for noninbred families, respectively) and was not sig-
nificantly reduced among patients with complex IV de-
ficiency ( and 0.75, for all families and non-R  0.77
inbred families, respectively). Interestingly, the sex ratio
was markedly skewed toward males being affected with
complex I deficiency ( and 1.45, for all familiesR  1.68
and for noninbred families, respectively; ; see tableP ! .1
2). This observation strongly suggests that one (or sev-
eral) X-linked recessive gene(s) accounts for complex I
deficiency in our series. Finally, the number of miscar-
riages was examined in our series (29 miscarriages, for
23 [15.6%] of 148 couples) and in each biochemical
subtype. No significant difference in the rate of miscar-
riages was noted when the different types of deficiencies
were compared.
Discussion
By studying a cohort of 157 patients with RC-enzyme
deficiency, we have observed that complex I, complex
IV, and complex IIV deficiencies show comparable fre-
quencies in our series. A variety of neuromuscular and
nonneuromuscular symptoms could have been observed,
but truncal hypotonia, growth retardation, cardiomy-
opathy, encephalopathy, and liver failure were the most
frequent symptoms. No obvious correlation between the
type of RC deficiency and the clinical presentation was
noted, but cardiomyopathy and liver failure were sig-
nificantly more frequent in complex I and complex IIV
deficiencies, respectively. Interestingly, the sex ratio of
the probands and affected sibs was skewed toward males
being affected with complex I deficiency, suggesting that
a significant proportion of patients may suffer from an
X-linked recessive disease, in this subgroup. Since car-
diomyopathy was significantly associated with complex
I deficiency in our series, it is tempting to hypothesize
that the excess of affected males with complex I defi-
ciency is accounted for (at least in part) by mutations
either in the NDUFA1 gene on chromosome Xq24,
which codes for a subunit of complex I (Zhuchenko et
al. 1996), or in the G4.5 gene on chromosome Xq28
(Bione et al. 1996), mutations of which are believed to
cause Barth syndrome (cardiomyopathy, cyclic neutro-
penia, and complex I deficiency) (Bolhuis et al. 1991).
In keeping with this hypothesis, Barth syndrome has
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been diagnosed in 2 of our 18 families with cardiomy-
opathy and complex I deficiency. The sex ratio as well
as the frequency of cardiomyopathy remain significantly
elevated among families with complex I deficiency, even
after exclusion of these 2 families.
The wide clinical heterogeneity associated with RC
deficiency has been reported often, particularly among
children (Robinson et al. 1987; Rowland et al. 1991;
Robinson 1993; Jackson et al. 1995; Pitka¨nen et al.
1996; Rahman et al. 1996). However, the relatively small
size of the patient cohorts studied has made it difficult
to consider consanguinity, parental age, and sex ratio in
order to trace the genetic origin of these diseases.
No significant increase in the mean parental age at
time of birth of the probands was noted, suggesting that
dominant de novo mutations in RC deficiency are rel-
atively unlikely. However, the remarkably high rate of
parental consanguinity both in our entire series and in
the subgroup of North African patients strongly sup-
ports the view that an autosomal recessive mode of in-
heritance is involved in complex IV and complex IIV
deficiencies. Additional evidence of nuclear-gene involve-
ment is provided by (1) results from complementation
studies of RC-deficient fibroblasts, with control fibro-
blast strains lacking mtDNA (rho cells) (Tiranti et al.
1995); (2) the low overall rate (6.85%) of mtDNA mu-
tations/deletions in RC deficiency (Wong and Liang
1997); and (3) the formal exclusion of mitochondrial
genes in large series of patients with complex I (Buddiger
et al. 1997), complex III (Valnot et al. 1997), or complex
IV (Parfait et al. 1997) deficiency.
Yet, although most cases of RC deficiency are likely
to follow nuclear inheritance, in humans, very little is
known regarding the disease-causing nuclear genes. In-
deed, to our knowledge, systematic sequence analysis of
nuclear genes encoding subunits of complexes I, III, and
IV has failed to detect any deleterious mutations in pa-
tients with RC defects. Apart from a flavoprotein gene
mutation in succinate dehydrogenase deficiency (Bour-
geron et al. 1995), no nuclear-gene mutations have been
identified thus far in genes encoding the catalytic sub-
units of the RC.
On the other hand, the nuclear genes controlling the
structure, assembly, and function of the RC complexes
are attractive candidate genes for RC deficiencies, es-
pecially since mutations of their yeast homologues are
known to cause the respiration-deficient petite pheno-
types. Although little is known regarding these genes in
humans, an increasing amount of information on mi-
tochondrial biogenesis in lower eukaryotes (e.g., Sac-
charomyces cerevisiae) has been made available. In par-
ticular, the import, assembly, and metabolism of the
protein components of the RC complexes in yeast are
known to be under the control of numerous nuclear
genes, mutations of which result in petite phenotypes
(Tzagoloff and Dieckmann 1990). We expect that on-
going studies aimed at identifying and mapping the hu-
man orthologues of the yeast genes involved in biogen-
esis of the RC complexes will provide attractive
candidate nuclear genes to be tested by homozygosity
mapping in the inbred families reported in our series. In
conclusion, this study provides what we believe to be
the first population-genetics evidence of autosomal re-
cessive gene involvement in most mitochondrial disor-
ders, an observation that is highly relevant to genetic
counseling for these devastating conditions.
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